S everal reports leverage patterns in electronic medical record data to create algorithms to optimize outcomes in healthcare. [1] [2] [3] More recently, there has been an increasing call for the use of clinical trial data repositories. 4 Open clinical trial data sharing has allowed us to evaluate the generalizability of algorithms to predict response to thiopurines in patients with inflammatory bowel disease (IBD). Yale University Open Data Access (http://yoda.yale.edu/) is a data-sharing platform that provides access to multiple clinical trial datasets. Previously, we internally validated machine learning algorithms for both clinical and biological remission among patients on thiopurines. 2, 3 We sought to externally validate the previously developed algorithm to predict objective remission in the SONIC clinical trial of azathioprine, infliximab, or the combination of azathioprine and infliximab in Crohn's disease using open clinical trial data.
Thiopurines continue to be used as monotherapy or as part of combination therapy for the treatment of IBD. Worldwide, thiopurines are frequently used as a monotherapy as they remain a low-cost option for steroidsparing therapy. Experts in IBD rely on patterns in the complete blood count and differential (CBCD) and comprehensive chemistry (COMP) panels to monitor their patients, as thiopurine metabolites perform poorly in the evaluation of clinical response. 5 Metabolites have also failed to show benefit in 2 prospective randomized controlled trials. [6] [7] Patterns in the CBCD and COMP can be successfully used to predict objective remission with high accuracy, and have been internally validated. 3 
Methods
To externally validate this algorithm for objective remission, we used data from the SONIC multicenter, randomized, double-blind controlled trial in patients with moderate-to-severe Crohn's disease, treated in 3 arms with infliximab plus azathioprine, infliximab, or azathioprine (ClinicalTrials.gov, NCT00094458). We applied our algorithm to predict objective remission on thiopurine monotherapy in IBD to the SONIC trial dataset to provide an external validation. We hypothesized that this algorithm would be minimally helpful (area under the receiver-operating characteristic curve [AuROC] z 0.50) for patients in the infliximab alone arm, modestly helpful (AuROC z 0.60) for patients in the combination (infliximab þ azathioprine) arm, and quite helpful (AuROC z 0.75) in the patients treated with azathioprine monotherapy.
The initial trial randomized 508 patients, and details of this study can be found on the ClinicalTrials.gov website and in the corresponding publication. 8 We selected only those patients who had objective inflammation at entry to the study, defined by a C-reactive protein (CRP) >6 mg/L or documented endoscopic ulceration (ULCRTN field ¼ yes). Subjects who did not complete the week 26 visit (withdrawn) or those with no recorded CRP or ULCRTN value at week 26 (missing data) were not included in our analysis. In total, there were 244 inflamed subjects with complete data. Objective remission was defined by the absence of objective inflammation as defined by a CRP 6 mg/L and a response of "no" for the ULCRTN field at week 26. Subjects not in objective remission were defined based on a CRP >6 mg/L or ULCRTN field response of "yes." Of the 244 subjects analyzed, 77 achieved objective remission and 167 did not ( Figure 1A) .
Independent predictor variables included all of the values from the CBCD and COMP panels, and the patient's age calculated as the exact number of years. of 0.564, we were able to predict which patients achieved objective remission on thiopurine monotherapy with an AuROC of 0.76 ( Figure 1B) . The performance characteristics of this algorithm were also evaluated for subjects in the combination (infliximab and azathioprine) arm (AuROC ¼ 0.67), and for subjects in the infliximab monotherapy arm (AuROC ¼ 0.60), with diminishing results, as expected.
Discussion
These thiopurine algorithms provide an accurate, rapid, low-cost, and generalizable alternative to thiopurine metabolites to evaluate objective remission in patients with IBD on thiopurine therapy. These algorithms have been implemented and automated in an Epic electronic medical record (Epic Systems Corporation, Verona, WI) and standard clinical workflow.
In addition, we are now in the process of engaging other hospitals, predominantly in Taipei and Hong Kong where thiopurine use is more prevalent than in the United States, to do a prospective validation study using our algorithms.
It should be noted that there are limitations to our study that include the retrospective nature of evaluating our algorithm, as well as the generalizability. We hope that these issues will be addressed in a prospective study. 
